[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-358717-105":59,"doc-detail-358717-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","predicting-hormone-receptor-status-in-tumors-an-innovative-approach-using-breast-ultrasound-radiomics-combined-model","Predicting hormone receptor status in tumors - An innovative approach using breast ultrasound-radiomics combined model","","Hormone receptor (HR) status is a critical biomarker for treatment selection and prognosis in breast cancer, yet immunohistochemistry depends on invasive tissue samples and can miss tumor heterogeneity. A retrospective cohort of 186 pathologically confirmed invasive breast carcinoma cases was used to develop a combined ultrasound (US)-radiomics model for predicting HR status. B-mode US images were segmented, 463 radiomic features were extracted, and a radial basis function SVM was trained with leave-one-out cross-validation. Performance was assessed by AUC, accuracy, sensitivity, specificity, and 95% confidence intervals. The hybrid model reached AUC 0.728 (95% CI 0.701–0.755) and 67.9% accuracy, supporting noninvasive, radiation-free HR prediction.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/predicting-hormone-receptor-status-in-tumors-an-innovative-approach-using-breast-ultrasound-radiomics-combined-model/358717/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/predicting-hormone-receptor-status-in-tumors-an-innovative-approach-using-breast-ultrasound-radiomics-combined-model/358717.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":81},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What clinical role does hormone receptor (HR) status play in breast cancer?","Question",{"text":112,"@type":113},"HR status guides systemic treatment decisions and prognosis in breast cancer. It is determined by ER, PR, and HER-2 profiles.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is immunohistochemistry considered limited for HR status assessment?",{"text":117,"@type":113},"Immunohistochemistry relies on invasive tissue sampling and may not represent tumor heterogeneity well. It also carries procedural risks such as bleeding and infection.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the proposed model predict HR status?",{"text":121,"@type":113},"The study extracts 463 radiomic features from manually segmented B-mode ultrasound tumor regions and trains a radial basis function SVM using leave-one-out cross-validation, evaluating performance with AUC and related metrics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},358717,1790211309,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":81,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","®  \n Observational Study   \nPredicting hormone receptor status in tumors An innovative approach using breast ultrasound-radiomics combined model  \nXue Yin, MDa , Zhen Wang, PhDa ,* , Qinxian Zhao, PhDa , Xincun Zhang, BSca , Tian Sang, MDa , Changjie Shao, MDa  \n\n| Abstract\u003Cbr>Hormone receptor (HR) status is a critical biomarker used to formulate treatment programs and prognosis in breast cancer. Traditional immunohistochemistry relies on invasive tissue samples and may not accurately reflect tumor heterogeneity. Radiomicsis a noninvasive technique that involves extracting quantitative imaging characteristics from molecular profiles. The purpose of this study is to develop a combined ultrasound (US)-radiomics model to predict HR status in invasive breast cancer. A retrospective cohort of 186 patients with invasive breast carcinoma, which had been pathologically confirmed, was used in this study, comprising 150 cases (HR-positive (ER+/PR − , HER-2−)) and 36 cases (HR-negative (ER −/PR − , HER-2−)) . B-mode US images of the tumor regions were manually segmented, and 463 radiomic features were obtained. T tests, ANOVA, and recursive methods were applied to create a list of features. A support vector machine with a radial basis function kernel was trained using leaveone-out cross-validation. To measure model performance, accuracy, sensitivity, specificity, area under the curve (AUC), and 95% confidence intervals (CIs) were used. The hybrid model had an AUC of 0.728 (95% CI: 0.701–0.755) and an accuracy of 67.9. The model with the highest AUC (0 .753, 95% CI: 0.7240.782) was the internal echo-based model. HR-negative tumors were larger, had higher marker of proliferation (Ki-67) indices, and showed greater textural heterogeneity than HR-positive lesions (P \u003C .05) . US-radiomics combined modeling is a promising, cost-effective, and radiation-free approach to noninvasive imaging that can predict HR status in breast cancer. US biomarkers can be quantitative, providing insights into tumor microstructure to personalize diagnostic and therapeutic approaches. |\n| --- |\n| Abbreviations: AUC = area under the curve, ER = estrogen receptor, HER-2 = human epidermal growth factor receptor 2 , HR = hormone receptor, Ki-67 = marker of proliferation, LOOCV = leave-one-out cross-validation, PR = progesterone receptor, ROC = receiver operating characteristic, ROI = region of interest, SVM = support vector machine, US = ultrasound. |\n| Keywords: breast cancer, hormone receptor, machine learning, noninvasive diagnosis, ultrasound radiomics |\n\n1. Introduction  \nBreast cancer is the most commonly diagnosed malignancy anda major cause of cancer-related deaths in women worldwide, with 2.3 million new cases and 670,000 deaths worldwide in 2022 alone. [1] This, along with the increasing global burden, underscores the need for improved diagnostic and prognostic strategies that enable precise tumor diagnosis and targeted therapeutic planning. A fundamental biomarker is HR status (i.e., estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2)), which dictates systemic treatment therapy and prognosis in breast cancer.[2,3]  \nProper detection of receptor profiles is crucial for prioritizing patients for endocrine treatment or HER-2-target therapy.[4,5]  \nConventionally, HR expression is determined by immunohistochemistry of a tissue sample either via core needle biopsy or surgical resection. Histopathological analysis is the gold standard, but has some disadvantages, such as intratumor heterogeneity, limited representativeness of the whole tumor microenvironment, and procedural risks, including bleeding and infection. [6,7] As a result, the development of noninvasive imaging biomarkers that may reflect the underlying molecular and histopathological features of tumors without requiring tissue extraction is gaining traction. [8,9]  \nThis study received funding from the Collaborative Academic Innovation Project of Sha","cbCaieHLVvwFQocC","https://ap.wps.com/l/cbCaieHLVvwFQocC","pdf",783281,"English","# Introduction\n## Motivation and clinical significance of HR status\n## Limitations of immunohistochemistry\n## Rationale for noninvasive imaging biomarkers\n## Study support and declarations\n## Ultrasound in breast cancer imaging","[{\"question\":\"What clinical role does hormone receptor (HR) status play in breast cancer?\",\"answer\":\"HR status guides systemic treatment decisions and prognosis in breast cancer. It is determined by ER, PR, and HER-2 profiles.\"},{\"question\":\"Why is immunohistochemistry considered limited for HR status assessment?\",\"answer\":\"Immunohistochemistry relies on invasive tissue sampling and may not represent tumor heterogeneity well. It also carries procedural risks such as bleeding and infection.\"},{\"question\":\"How does the proposed model predict HR status?\",\"answer\":\"The study extracts 463 radiomic features from manually segmented B-mode ultrasound tumor regions and trains a radial basis function SVM using leave-one-out cross-validation, evaluating performance with AUC and related metrics.\"}]","Predicting hormone receptor status in tumors - An innovative approach using breast ultrasound-radiomics combined model | PDF",1790135062]